Dr. Larry Mahan, CEO of OB Pharmaceuticals, attended the JP Morgan Healthcare Conference

LONDON, ONTARIO January 12, 2019 -- Dr. Larry Mahan, CEO of OB Pharmaceuticals, attended the JP Morgan Healthcare Conference week (Jan. 7-10) in San Francisco, CA to meet with prospective investors for the company's upcoming Series A capital raise initiative and with key pharmaceutical companies in the epilepsy therapeutic market as potential strategic partners moving forward. The company is concluding its preclinical lead development phase for TD567 and will be seeking funding to complete IND/CTA-enabling GLP toxicology studies prior to filing its IND and CTA to proceed into clinical trials. Meetings resulted in a number of follow-on diligence actions by investors and interested pharmaceutical business development representatives.

About J.P. Morgan

The annual J.P. Morgan Healthcare Conference, held each January in San Francisco, CA, brings thousands of investors from around the world together. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.

About OB Pharmaceuticals

OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.